002603 以岭药业
已收盘 07-16 15:00:00
资讯
新帖
简况
以岭药业:公司申报注册的第一个经典名方品种半夏白术天麻颗粒获受理
证券之星 · 07-11
以岭药业:公司申报注册的第一个经典名方品种半夏白术天麻颗粒获受理
以岭药业:发挥企业创新优势,助推行业发展迈向更高阶段
中国经济时报 · 07-10
以岭药业:发挥企业创新优势,助推行业发展迈向更高阶段
以岭药业创新药G201-Na获批临床,剑指辅助生殖痛点,一季度净利润逆势增长7.25%
新浪证券 · 07-08
以岭药业创新药G201-Na获批临床,剑指辅助生殖痛点,一季度净利润逆势增长7.25%
以岭药业(002603.SZ):化药创新药“G201-Na胶囊”临床试验申请获得批准
智通财经 · 07-07
以岭药业(002603.SZ):化药创新药“G201-Na胶囊”临床试验申请获得批准
以岭药业:通心络治疗脑梗死研究获突破性成果
证券之星 · 07-03
以岭药业:通心络治疗脑梗死研究获突破性成果
7月3日以岭药业涨5.78%,汇添富中证中药ETF基金重仓该股
证券之星 · 07-03
7月3日以岭药业涨5.78%,汇添富中证中药ETF基金重仓该股
产品被列入冠脉介入指南,以岭药业股价大涨超5%
证券之星 · 07-03
产品被列入冠脉介入指南,以岭药业股价大涨超5%
以岭药业:多渠道推广八子产品销售
证券之星 · 07-02
以岭药业:多渠道推广八子产品销售
以岭药业公布国际专利申请:“三环稠杂环类PDE3/4双重抑制剂及其制备方法与应用”
证券之星 · 07-01
以岭药业公布国际专利申请:“三环稠杂环类PDE3/4双重抑制剂及其制备方法与应用”
科研创新实力凸显 以岭药业荣登2025中国中药研发实力排行榜TOP50、位列第二
全景网 · 06-26
科研创新实力凸显 以岭药业荣登2025中国中药研发实力排行榜TOP50、位列第二
以岭药业理论输出形成竞争力,用国际“金标准”讲好中医药故事
中国经济时报 · 06-18
以岭药业理论输出形成竞争力,用国际“金标准”讲好中医药故事
以岭药业荣膺金羚奖“2025年度ESG社会责任实践领先企业”
证券之星 · 06-13
以岭药业荣膺金羚奖“2025年度ESG社会责任实践领先企业”
以岭药业新提交1件商标注册申请
证券之星 · 05-31
以岭药业新提交1件商标注册申请
每周股票复盘:以岭药业(002603)高管增持3000股,股价下跌3.02%
证券之星 · 05-24
每周股票复盘:以岭药业(002603)高管增持3000股,股价下跌3.02%
国泰海通维持以岭药业增持评级 目标价16.5元
证券之星 · 05-22
国泰海通维持以岭药业增持评级 目标价16.5元
以岭药业:5月19日高管周晓林增持股份合计3000股
证券之星 · 05-20
以岭药业:5月19日高管周晓林增持股份合计3000股
世界品牌莫干山大会|以岭药业被授予“品牌创新先锋企业”称号
证券之星 · 05-12
世界品牌莫干山大会|以岭药业被授予“品牌创新先锋企业”称号
以岭药业:过去四年研发上市5个创新中药 系获批数量最多企业之一
全景网 · 05-12
以岭药业:过去四年研发上市5个创新中药 系获批数量最多企业之一
以岭药业张蕴龄:全链条创新锻造中医药新质生产力
经济参考网 · 05-11
以岭药业张蕴龄:全链条创新锻造中医药新质生产力
世界品牌莫干山大会|以岭药业张蕴龄:用“金标准”向世界讲好中医药故事
IT新闻网 · 05-11
世界品牌莫干山大会|以岭药业张蕴龄:用“金标准”向世界讲好中医药故事
加载更多
公司概况
公司名称:
石家庄以岭药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-07-28
主营业务:
石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是通心络胶囊、参松养心胶囊、芪苈强心胶囊、连花清瘟胶囊/颗粒、连花清咳片、津力达颗粒、通络明目胶囊、益肾养心安神片、解郁除烦胶囊、枣椹安神口服液、养正消积胶囊、参灵蓝胶囊、八子补肾胶囊、夏荔芪胶囊、乳结泰胶囊、妇血安片。公司先后多次承担国家及省部级科研计划项目,荣获国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项,获得中药发明专利400余项。
发行价格:
34.56
{"stockData":{"symbol":"002603","market":"SZ","secType":"STK","nameCN":"以岭药业","latestPrice":15.1,"timestamp":1752649410000,"preClose":14.79,"halted":0,"volume":22768069,"delay":0,"changeRate":0.021,"floatShares":1377000000,"shares":1671000000,"eps":-0.4205,"marketStatus":"已收盘","change":0.31,"latestTime":"07-16 15:00:00","open":14.81,"high":15.15,"low":14.75,"amount":341000000,"amplitude":0.027,"askPrice":15.11,"askSize":1868,"bidPrice":15.1,"bidSize":523,"shortable":0,"etf":0,"ttmEps":-0.4205,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752715800000},"marketStatusCode":5,"adr":0,"adjPreClose":14.79,"symbolType":"stock","openAndCloseTimeList":[[1752629400000,1752636600000],[1752642000000,1752649200000]],"highLimit":16.27,"lowLimit":13.31,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1670705376,"isCdr":false,"pbRate":2.34,"roa":"--","roe":"3.14%","epsLYR":-0.4337,"committee":-0.61867,"marketValue":25228000000,"turnoverRate":0.0165,"status":0,"floatMarketCap":20790000000},"requestUrl":"/m/hq/s/002603","defaultTab":"news","newsList":[{"id":"2550608742","title":"以岭药业:公司申报注册的第一个经典名方品种半夏白术天麻颗粒获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2550608742","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550608742?lang=zh_cn&edition=full","pubTime":"2025-07-11 09:24","pubTimestamp":1752197059,"startTime":"0","endTime":"0","summary":"7月10日,以岭药业(002603.SZ)公告称,公司7月9日收到国家药品监督管理局核准签发的《受理通知书》,申请事项为境内生产药品注册上市许可,产品名称为半夏白术天麻颗粒。半夏白术天麻颗粒是公司申报注册的第一个经典名方品种,品种处方为国家中医药管理局2018年4月发布的《古代经典名方目录(第一批)》中的第81首处方,出自清代程国彭《医学心悟》。截至本公告披露之日,中国境内(不包括港澳台地区)尚无半夏白术天麻颗粒获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025071100007063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002603","BK0046","BK0097","BK0042"],"gpt_icon":0},{"id":"2550492736","title":"以岭药业:发挥企业创新优势,助推行业发展迈向更高阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2550492736","media":"中国经济时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550492736?lang=zh_cn&edition=full","pubTime":"2025-07-10 18:15","pubTimestamp":1752142555,"startTime":"0","endTime":"0","summary":"作为中医药现代化的标杆企业之一, 以岭药业 成立30多年来始终坚持传承创新发展,与国家战略同频,与行业发展共振,与人民需求相和,为行业高质量发展提供了生动实践样本。在生产端,以岭药业建立高标准质量管理体系,强化药品质量重点环节和全流程管理,用心把好药品质量安全关,保证人民群众用药安全有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710182921a6a16c4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710182921a6a16c4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002603","561510","BK0042","562390","BK0097","BK0239","BK0046","BK0188"],"gpt_icon":0},{"id":"2549451869","title":"以岭药业创新药G201-Na获批临床,剑指辅助生殖痛点,一季度净利润逆势增长7.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549451869","media":"新浪证券","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549451869?lang=zh_cn&edition=full","pubTime":"2025-07-08 15:13","pubTimestamp":1751958780,"startTime":"0","endTime":"0","summary":" 7月7日,石家庄以岭药业(维权)的一纸公告,悄然在创新药领域激起涟漪。 其自主研发的化学1类新药G201-Na胶囊,成功获得国家药监局临床试验批文,目标直指辅助生殖中棘手的“提前排卵”难题。 此番获批的G201-Na,身份非同一般,属于《药品注册分类》中创新程度最高的“化学药品1类”。 这背后,是对千亿级辅助生殖市场核心痛点的精准发力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/focus/2025-07-08/doc-infetywp5763768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","002603","06978"],"gpt_icon":0},{"id":"2549539553","title":"以岭药业(002603.SZ):化药创新药“G201-Na胶囊”临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2549539553","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549539553?lang=zh_cn&edition=full","pubTime":"2025-07-07 19:03","pubTimestamp":1751886191,"startTime":"0","endTime":"0","summary":"智通财经APP讯,以岭药业(002603.SZ)发布公告,公司于2025年7月7日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,涉及药品:“G201-Na胶囊”。G201-Na是由石家庄以岭药业股份有限公司研发的化学药品1类新药,为小分子促性腺激素释放激素(GnRH)受体拮抗剂。药物通过与垂体GnRH受体竞争性结合,抑制垂体性腺轴,减少内源性促黄体生成素(LH)和卵泡刺激素(FSH)的生成和释放,降低雌激素水平,从而治疗雌激素依赖的相关疾病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","002603","BK1161","BK1576","BK0239","BK0188","BK0042","BK0097","BK0046","BK1141","159992","03347","BK1574","BK1583"],"gpt_icon":0},{"id":"2548025768","title":"以岭药业:通心络治疗脑梗死研究获突破性成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2548025768","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548025768?lang=zh_cn&edition=full","pubTime":"2025-07-03 20:51","pubTimestamp":1751547086,"startTime":"0","endTime":"0","summary":"通心络胶囊是治疗冠心病、脑梗死的专利创新中药,为国家医保甲类品种、国家基本用药目录品种。同时,“通心络治疗脑小血管病随机、双盲、安慰剂对照、多中心研究”也在稳步开展中,为临床应用提供更多证据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070300036232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0046","BK0188","002603","BK0239","BK0042"],"gpt_icon":0},{"id":"2548796748","title":"7月3日以岭药业涨5.78%,汇添富中证中药ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2548796748","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548796748?lang=zh_cn&edition=full","pubTime":"2025-07-03 16:29","pubTimestamp":1751531347,"startTime":"0","endTime":"0","summary":"证券之星消息,7月3日以岭药业涨5.78%,收盘报15.0元,换手率5.79%,成交量79.71万手,成交额11.95亿元。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为汇添富基金的汇添富中证中药ETF。汇添富中证中药ETF目前规模为21.49亿元,最新净值1.0522,较上一交易日下跌0.46%,近一年上涨0.42%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070300026178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["560080","BK0046","BK0188","BK0042","002603","BK0097","159647","BK0239"],"gpt_icon":0},{"id":"2548882890","title":"产品被列入冠脉介入指南,以岭药业股价大涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548882890","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548882890?lang=zh_cn&edition=full","pubTime":"2025-07-03 10:27","pubTimestamp":1751509677,"startTime":"0","endTime":"0","summary":"7月3日,以岭药业股价大涨超5%。消息面上值得关注的是近期,第二十九届东北心血管病大会在沈阳召开,《中国经皮冠状动脉介入治疗指南》正式发布。此外,作为创新中药领域的龙头企业,以岭药业始终将科技创新视为企业发展的核心驱动力。在产品管线上,以岭药业已拥有专利新药17个,另有2个创新中药已申报生产,6个中药处于临床阶段。这些丰富的在研产品,随着后续相继上市,有望为以岭药业的长期发展注入源源不断的动力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025070300011684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0046","BK0188","BK0097","BK0239","BK0042"],"gpt_icon":0},{"id":"2548864073","title":"以岭药业:多渠道推广八子产品销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2548864073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548864073?lang=zh_cn&edition=full","pubTime":"2025-07-02 17:03","pubTimestamp":1751446995,"startTime":"0","endTime":"0","summary":"证券之星消息,以岭药业(002603)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问:八子补肾胶囊的推进太慢了。要想想办法,花了那么多钱搞研究,可是宣传销售不行。以岭药业回复:投资者您好,目前公司在零售和电商多渠道加大力度推广八子产品的销售。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070200027083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0188","BK0046","BK0239","BK0097","BK0042"],"gpt_icon":0},{"id":"2548381058","title":"以岭药业公布国际专利申请:“三环稠杂环类PDE3/4双重抑制剂及其制备方法与应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2548381058","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548381058?lang=zh_cn&edition=full","pubTime":"2025-07-02 06:02","pubTimestamp":1751407359,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示以岭药业(002603)公布了一项国际专利申请,专利名为“三环稠杂环类PDE3/4双重抑制剂及其制备方法与应用”,专利申请号为PCT/CN2024/138682,国际公布日为2025年6月19日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来以岭药业已公布的国际专利申请1个。结合公司2024年年报财务数据,2024年公司在研发方面投入了8.27亿元,同比减3.12%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070200003545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","002603","BK0046","BK0239","BK0042"],"gpt_icon":0},{"id":"2546835127","title":"科研创新实力凸显 以岭药业荣登2025中国中药研发实力排行榜TOP50、位列第二","url":"https://stock-news.laohu8.com/highlight/detail?id=2546835127","media":"全景网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546835127?lang=zh_cn&edition=full","pubTime":"2025-06-26 17:07","pubTimestamp":1750928820,"startTime":"0","endTime":"0","summary":"近日,2025PDI医药研发创新大会暨中国药品研发百强榜发布会在重庆盛大举行。全景网获悉,以岭药业凭借在中药研发领域的卓越表现,荣耀登榜2025中国中药研发实力排行榜TOP50,位居榜眼之位。截至目前,以岭药业拥有专利中药17个,覆盖8大临床疾病系统,其中心脑血管系统和感冒呼吸系统疾病用药领域已处于行业领先地位。军这些成果,无疑是以岭药业在中药研发领域强大实力和创新能力的有力证明。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626171012978fb2cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626171012978fb2cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0042","002603","BK0239","BK0097","BK0188","BK0046","562390","561510"],"gpt_icon":0},{"id":"2544927186","title":"以岭药业理论输出形成竞争力,用国际“金标准”讲好中医药故事","url":"https://stock-news.laohu8.com/highlight/detail?id=2544927186","media":"中国经济时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544927186?lang=zh_cn&edition=full","pubTime":"2025-06-18 16:27","pubTimestamp":1750235249,"startTime":"0","endTime":"0","summary":"循证医学这一国际公认评价药物疗效的“金标准”,成为了以岭药业打开国际市场大门的钥匙。以岭药业通过络病理论创新形成核心竞争力,用世界认可的研究数据讲好“中医药故事”,并以卓越产品收获海外认可,探索出了一条具有以岭特色的中医药国际化之路,为中医药走向世界贡献了重要力量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618172210a4b03b91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618172210a4b03b91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["562390","BK0097","561510","BK0188","BK0239","BK0042","BK0046","002603"],"gpt_icon":0},{"id":"2543864638","title":"以岭药业荣膺金羚奖“2025年度ESG社会责任实践领先企业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2543864638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543864638?lang=zh_cn&edition=full","pubTime":"2025-06-13 21:51","pubTimestamp":1749822715,"startTime":"0","endTime":"0","summary":"6月13日,由广东时代传媒集团主办的“2025ESG与高质量发展创新论坛”在北京举办。据悉,在高质量发展大背景下,时代传媒集团秉承长期主义,为鼓励ESG领先的企业与个人,特设立ESG“金羚奖”。以岭药业获得金羚奖“2025年度ESG社会责任实践领先企业”,进一步印证了其在科技创新和社会责任领域的卓越表现。值得一提的是,以岭药业坚持用实际行动践行ESG理念,把生产经营与促进乡村振兴、农民致富结合起来。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.stockstar.com/SS2025061300041629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","159717","161912","BK0188","BK0239","BK0042","BK0046","002603"],"gpt_icon":0},{"id":"2540821917","title":"以岭药业新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2540821917","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540821917?lang=zh_cn&edition=full","pubTime":"2025-06-01 04:56","pubTimestamp":1748724977,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日石家庄以岭药业股份有限公司新提交1件商标注册申请。商标申请详情如下:今年以来石家庄以岭药业股份有限公司新申请注册商标20件,截止目前公司共持有注册商标1140件,另有254件商标尚在注册申请中。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060100000141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0239","BK0188","BK0042","BK0097","BK0046"],"gpt_icon":0},{"id":"2537161336","title":"每周股票复盘:以岭药业(002603)高管增持3000股,股价下跌3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537161336","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537161336?lang=zh_cn&edition=full","pubTime":"2025-05-24 11:17","pubTimestamp":1748056628,"startTime":"0","endTime":"0","summary":"截至2025年5月23日收盘,以岭药业报收于14.73元,较上周的15.22元下跌3.22%。本周,以岭药业5月19日盘中最高价报15.26元。本周关注点股本股东变化 公司高管周晓林共增持公司股份3000.0股,占公司总股本为0.0002%股本股东变化根据5月20日市场公开信息、上市公司公告及交易所披露数据整理,以岭药业最新董监高及相关人员股份变动情况:2025年5月19日公司高管周晓林共增持公司股份3000.0股,占公司总股本为0.0002%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052400011199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","002603","BK0046","BK0239","BK0042"],"gpt_icon":0},{"id":"2537961970","title":"国泰海通维持以岭药业增持评级 目标价16.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537961970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537961970?lang=zh_cn&edition=full","pubTime":"2025-05-22 10:06","pubTimestamp":1747879610,"startTime":"0","endTime":"0","summary":"国泰海通5月20日发布研报,维持以岭药业增持评级,目标价位16.5元。截至报告日,公司最新收盘价为14.79元,较目标价有11.56%的上行空间。国泰海通预测,以岭药业2025年归母净利润10.98亿元,同比增长251.55%。主要财务指标与估值2025E2026E2027E营业总收入(亿元)90.28101.7112.94归母净利润(亿元)10.9813.2415.64每股收益(元)0.660.790.94市盈率22.4518.6315.77市净率2.262.11.94净资产收益率(%)10.111.312.3总资产收益率(%)7.88.59.2注:数据获取自研报正文以岭药业近一个月获得5份券商研报关注,平均目标价为17.59元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025052200008739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02611","002603"],"gpt_icon":0},{"id":"2536234610","title":"以岭药业:5月19日高管周晓林增持股份合计3000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2536234610","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536234610?lang=zh_cn&edition=full","pubTime":"2025-05-20 21:01","pubTimestamp":1747746091,"startTime":"0","endTime":"0","summary":"证券之星消息,根据5月20日市场公开信息、上市公司公告及交易所披露数据整理,以岭药业最新董监高及相关人员股份变动情况:2025年5月19日公司高管周晓林共增持公司股份3000.0股,占公司总股本为0.0002%。以岭药业近半年内的董监高及核心技术人员增减持详情如下:以岭药业的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流入3728.97万,融资余额增加;融券净流入11.33万,融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052000036102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","002603","BK0046","BK0239","BK0042"],"gpt_icon":0},{"id":"2534822027","title":"世界品牌莫干山大会|以岭药业被授予“品牌创新先锋企业”称号","url":"https://stock-news.laohu8.com/highlight/detail?id=2534822027","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534822027?lang=zh_cn&edition=full","pubTime":"2025-05-12 20:53","pubTimestamp":1747054421,"startTime":"0","endTime":"0","summary":"5月9日至11日,2025世界品牌莫干山大会在浙江德清举行。在参考消息报社10日主办的“2025企业品牌国际传播论坛”上,以岭药业获评“品牌创新先锋企业”称号,其案例入选参考消息报社·参考智库发布的《中国企业海外传播力分析报告》。值得注意的是,以岭药业用“国际标准”来讲述中医药故事,取得了重磅成果。以岭药业推进海外品牌影响力建设的系统性实践,为促进中西方医学的交流互鉴作出了贡献。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025051200032039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","002603","BK0188","BK0097","BK0239","BK0046"],"gpt_icon":0},{"id":"2535522734","title":"以岭药业:过去四年研发上市5个创新中药 系获批数量最多企业之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2535522734","media":"全景网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535522734?lang=zh_cn&edition=full","pubTime":"2025-05-12 17:58","pubTimestamp":1747043880,"startTime":"0","endTime":"0","summary":"5月12日下午,以岭药业(002603.SZ)2024年度业绩网上说明会成功在全景网举办。交流会中,问及研发相关事宜,以岭药业独立董事柴振国表示,公司始终将科技创新作为企业发展的核心竞争力,在研发投入方面保持了持续增长态势。过去四年,公司研发上市了5个创新中药,是获批数量最多的企业之一。未来公司仍会继续加大研发投入,提高研发产出率,不断丰富产品阵列。(全景网)更多业绩说明会详情,请点击:https://rs.p5w.net/html/146753.shtml","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505130801159757aa0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505130801159757aa0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002603","BK0046","BK0239","BK0042","561510","562390","BK0188","BK0097"],"gpt_icon":0},{"id":"2534869642","title":"以岭药业张蕴龄:全链条创新锻造中医药新质生产力","url":"https://stock-news.laohu8.com/highlight/detail?id=2534869642","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534869642?lang=zh_cn&edition=full","pubTime":"2025-05-11 19:12","pubTimestamp":1746961930,"startTime":"0","endTime":"0","summary":"产业链创新也是以岭药业推进全链条创新的重要一环。对于未来发展,张蕴龄表示,以岭药业将紧抓科研攻关和科技创新成果转化,为中医药产业高质量发展注入不竭动力;同时进一步加强国际交流与合作,将中医药产品推向全球,为构建人类卫生健康共同体贡献力量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250511191457a6daff4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250511191457a6daff4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002603","BK0239","BK0188","BK0042","561510","BK0046","562390","BK0097"],"gpt_icon":0},{"id":"2534402755","title":"世界品牌莫干山大会|以岭药业张蕴龄:用“金标准”向世界讲好中医药故事","url":"https://stock-news.laohu8.com/highlight/detail?id=2534402755","media":"IT新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534402755?lang=zh_cn&edition=full","pubTime":"2025-05-11 15:36","pubTimestamp":1746948969,"startTime":"0","endTime":"0","summary":"5月9日至11日,以“品牌,让世界更美好”为主题的2025世界品牌莫干山大会在浙江德清拉开帷幕。张蕴龄表示,作为创新中药企业,以岭药业自创立30多年来,始终秉承“继承创新,造福人类”的企业宗旨,持续助力推动中医药现代化、产业化、走向世界。张蕴龄表示,以岭药业将与各界一道,致力于把中医药宝库保护好、传承好、发展好,为建设健康中国和推动构建人类卫生健康共同体贡献力量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051116003097560989&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051116003097560989&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0046","BK0188","BK0042","002603","BK0097","562390","561510","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752668789292,"stockEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":0.0186},{"period":"3month","weight":0.1171},{"period":"6month","weight":-0.0574},{"period":"1year","weight":-0.0381},{"period":"ytd","weight":-0.0762}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.0379},{"period":"3month","weight":0.0699},{"period":"6month","weight":0.0831},{"period":"1year","weight":0.1785},{"period":"ytd","weight":0.0457}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石家庄以岭药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"185292人(较上一季度增加1.53%)","perCapita":"7430股","listingDate":"2011-07-28","address":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","registeredCapital":"167070万元","survey":" 石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是通心络胶囊、参松养心胶囊、芪苈强心胶囊、连花清瘟胶囊/颗粒、连花清咳片、津力达颗粒、通络明目胶囊、益肾养心安神片、解郁除烦胶囊、枣椹安神口服液、养正消积胶囊、参灵蓝胶囊、八子补肾胶囊、夏荔芪胶囊、乳结泰胶囊、妇血安片。公司先后多次承担国家及省部级科研计划项目,荣获国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项,获得中药发明专利400余项。","listedPrice":34.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"以岭药业,002603,以岭药业股票,以岭药业股票老虎,以岭药业股票老虎国际,以岭药业行情,以岭药业股票行情,以岭药业股价,以岭药业股市,以岭药业股票价格,以岭药业股票交易,以岭药业股票购买,以岭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}